2004 Vol. 28, No. 4

Display Method:
Gene transfer technology and genetic radioisotope targeting therapy
WANG Jia-qiong, WANG Zi-zheng
2004, 28(4): 145-149.
Abstract:
With deeper cognition about mechanisms of disease at the cellular and molecular level, gene therapy has become one of the most important research fields in medical molecular biology at present. Gene transfer technology plays an important role during the course of gene therapy, and further improvement should be made about vectors carrying target gene sequences. Also, gene survey is needed during gene therapy, and gene imaging is the most effective method. The combination of gene therapy and targeted radiotherapy, that is,"Genetic Radioisotope Targeting Therapy", will be a novel approach to tumor gene therapy.
Radioimmunotherapy for malignant glioma
GAO Yun-chao
2004, 28(4): 149-152.
Abstract:
Malignant glioma is treated mainly by surgery with chemotherapy and external radiotherapy as adjuvant remedies. Survival time can be prolonged if appropriate radioimmunotherapy is employed as another concurrent alternative. Per-clinical, clinical phase I and II studies of 131I and 90Y labeled anti-tenascin monoclonal antibodies in the treatment of malignant glioma have resulted in satisfactory therapeutic efficacy.
The research vicissitudes of hypothyroidism after 131I therapy for hyperthyroidism
CHEN Zai-jun, JIANG Ning-yi
2004, 28(4): 153-157.
Abstract:
A Retrospective analysis of hypothyroidism data after iodine-131 therapy for hyperthy-roidism during about 60-year period was performed. The aim of this work was to discuss incidence of hypothyroidism occurring after iodine-131 therapy for hyperthyroidism, influence factors of hypothyroidism and farther investigative problem.
Synthetic prevention and treatment for hypothyroidism after rdioiodine therapy hyperthyroidism
LI Shi-yun
2004, 28(4): 157-159.
Abstract:
Hypothyroidism is main complication after 131I therapy for hyperthyroidism in Graves' dis-ease. The hypothyroidism restricts its popular application that 131I treatment for Graves' disease. In clinic practice, different factors of every patient, involved case selection, sensitivity estimation, unite using medicine before 131I therapy are analysed, and synthetic measures for post treatment examination, transient hypothyroidism and permanent hypothyroidism after 131I therapy are discussed.
Colloidal rhenium and its application
WU Tao, LIU Chang-zheng
2004, 28(4): 160-162.
Abstract:
The most useful colloidal rhenium can be classified into two kinds according to its radionu-clide:the 188 Re labelled colloid and the colloidal rhenium labeled with other radionuclide. Rhenium-188 sulphur colloid has been shown to be an effective treatment as a radiation synovectomy agent. 188Re-labeled colloid, in addition was used to evaluate the effectiveness of this agent on some tumors such as melanoma, liver cancer in mice. For mapping sentinel nodes in lymphoscintigraphy, 99Tcm labeled rhenium colloid is a suitabl agent.
Role of Fusion in Accurate Radiotherapy
FAN Ting-yong, LI Jian-bin, YU Jin-ming
2004, 28(4): 163-165.
Abstract:
The technique of fusing different imaging modalities is currently being investigated in radiotherapy treatment planning, especially in accurate radiotherapy. It has a significant impact in the modern era of accurate radiotherapy. It makes a clear distinction of tumor and modifies the false positive or false negative lesions found by single imaging modality and minimizes the variation of the target volumes contoured by different oncologists.
The accuracy of using MRI in the localization of stereotactic radiotherapy
DIAO Huan-rong
2004, 28(4): 166-168,191.
Abstract:
CT and MRI are the usual methods being used in the localization of stereotactic radiotherapy (SRT). Each of the m has its own advantage. One of the major disadvantages of MRI is its image distortion, which affects the accuracy of the localization of SRT and the veracity of the dose distribution. Therefore, there are many arguments on the use of MRI in the localization. This article reviewed the principle of the use of MRI in the localization, the origin of the distortion, the magnitude of the error and its affecting factors, the corresponding solutions.
siRNA and tumor radiotherapy
LIU Guang-wei, GONG Shou-liang
2004, 28(4): 169-172.
Abstract:
Recently, many radio oncology researchers had gained some good curative effects on DNA damage repair inhibited and tumor cell death increased by blocking key control genes in the course of DNA repair with specific blocking agents. Otherwise, the blocking agents have many defects, which extremely limited its application on curing tumor. Since small interference RNA (siRNA) technology was discovered, its powerful function of blocking expressible specific protein in eukaryocytes was attented by many researchers. Meanwhile, this technology admirably resolved mentioned above problems caused by using the blocking agents, which provided a new way for tumor radio gene therapy.
Status of the research on radioprotective drugs and treatment of radiation damage by cytokines
MIN Rui
2004, 28(4): 173-178.
Abstract:
Nitroxide, amifostine and steroids are most considered as candidates of radioprotective drug. Amifostine is the first radioprotective drug used in radiotherapy approved by FDA(Food and Drug Administration)of USA in 1999. The use of the cytokine in treatment of the radiation damage has been developed from single cytokine which just stimulates one cell population to the combination of cytokines which function as both hematopoitic cells and hematopoitic microenvironment. Therapeutic effect of radiation damage has been significantly improved by use of cytokine combination.
Present investigation of radiation brain injury
LIU Qiang
2004, 28(4): 178-181.
Abstract:
Review the present investigation in pathogenesis, clinical symptom, diagnosis and treatment of radiation brain injury. The basic pathology is apoptosis of the vascular endothelial cell and oligodendrocyte. Cytokine and neural stem cell transplantation will make great future for treatment of radiation brain injury.
The molecular mechanism of gene-radiotherapy of tumor
ZHU Xian
2004, 28(4): 182-184.
Abstract:
Gene-radiotherapy of tumor is a new method which is induced by ionizing radiation. The molecular mechanism is to activate various molecular target by many ways and induce the apopatosis of tumor cell. It is a gene therapy based on the radiation-inducible property of the Egr-1 gene. It has good application prospect in therapy of tumor.
Three dimensional conformal radiotherapy and intensity-modulated radiotherapy
WU Wei-zhang
2004, 28(4): 185-188.
Abstract:
Three-dimensional conformal radiotherapy is a mostly-used external radiotherapy for some tumors, e.g. prostate carcinoma, head and neck cancer, breast cancer and lung cancer ect. Compared with the conventional radiotherapy, it can improve the dose to the target area in the tumor and reduce the ones to the proximal normal tissues and in return, decreases the probabilities of irradiation induced acute and long-term effects. Developed on the technology basis of conventional conformal radiotherapy, intensity modulated radiotherapy (IMRT) modulates the intensity spatial distribution in the incident beam, obtaining much better therapeutic effect.
The research status of BNCT technique
ZHANG Xiao-min, ZHANG Wen-zhong, LUO Yi-sheng
2004, 28(4): 188-191.
Abstract:
The principle of boron neutron capture therapy(BNCT), the correlated technique and the latest developments were mainly described in the article. The methods for production of epithermal neutron beam, i. e, nuclear reactor send particle accelerators and the boron compounds used in BNCT were particularly discussed, the article supplies references to BNCT research.